SCHEMBL90718

SCHEMBL90718

COCCCOc1cc(N)c(F)cc1C(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
GFER P55789 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
RECQL P46063 1/20 0.37
P2RX3 P56373 4/20 0.36
P2RX2 Q9UBL9 4/20 0.36
REN P00797 2/20 0.35
KCNH2 Q12809 2/20 0.35
ADRA2A P08913 1/20 0.32
CYP2D6 P10635 1/20 0.32
PKM P14618 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89783 0.80 KDM4E (0.34) POLBGAAL3MBTL1CYP1A2KMT2A
SCHEMBL2314552 0.77 L3MBTL1 (0.36) POLBGAAL3MBTL1CYP1A2KMT2A
SCHEMBL89538 0.77 TAAR1 (0.37) POLBGAAL3MBTL1CYP1A2KMT2A
SCHEMBL90719 0.76 PTGES (0.40) POLBKMT2AMEN1CYP3A4RECQL
SCHEMBL90611 0.75 REN (0.39) L3MBTL1CYP1A2KMT2AMEN1CYP3A4
SCHEMBL25600576 0.70 L3MBTL1 (0.46) L3MBTL1CYP1A2KMT2AMEN1CYP3A4
SCHEMBL9685009 0.70 EGFR (0.34) POLBL3MBTL1KMT2AMEN1KDM4E
SCHEMBL89396 0.70 SLC6A2 (0.41) L3MBTL1CYP1A2KMT2AMEN1CYP3A4
SCHEMBL8879337 0.70 L3MBTL1 (0.48) POLBGAAL3MBTL1KMT2AMEN1
SCHEMBL15087918 0.69 MEN1 (0.38) L3MBTL1CYP1A2KMT2AMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 POLB 589/4885GAA 309/4885GFER 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.